This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Sequenom CEO Presents At 30th Annual J.P. Morgan Healthcare Conference (Transcript)

Sequenom, Inc. ( SQNM)

30th Annual J.P. Morgan Healthcare Conference

January 12, 2012, 10:30 a.m. ET

Executi ve

Harry Hixson Jr. - Chairman and CEO

Presentation

Unidentified Analyst

All right. We’re going to go ahead and get started. Welcome to day four of the J.P. Morgan Healthcare Conference. This morning we have Sequenom and Dr. Harry Hixson, who is Chairman and CEO. Please silent your cell phones and the breakout will be in the Olympic Room.

Harry Hixson Jr.

Thank you, Allen. And thanks very much to J.P. Morgan for inviting us to present here at this the most important healthcare conference of the year. I’m also very pleased to be able to treat you today and to tell you about the outstanding year that Sequenom team had in 2011, and little bit of our plans going forward for 2012 and beyond.

I’d like to remind you that we are going to be making some forward-looking statements and you should carefully read this safe harbor statement as well.

Sequenom is composed of two operating segments, the first is our original genetic analysis business, we sell a MALDI-TOF mass spectrometer, consumable reagents and research use only panels for translational medicine OncoCarta and ADME panel for drug development. The other segment is molecular diagnostics business, which is centered in our Sequenom Center for Molecular Medicine.

I’m very pleased to report that for 2011 our revenues were up approximately 23% over 2010, just to remind you that those are preliminary and unaudited numbers. We are very pleased that in the very adverse environment in 2011 that our genetic analysis business should a 6% growth in revenue for the year and actually each quarter during the year, we were better than the same quarter in the previous year.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs